Traws Pharma completes Phase I studies with tivoxavir marboxil

Traws Pharma (TRAW) announced completion of Phase I clinical studies of its investigational one-dose influenza therapy, tivoxavir marboxil, for the treatment or prevention of H5N1 bird flu. “We believe that our clinical data in healthy volunteers support accelerated development of tivoxavir marboxil in response to the growing threat of bird flu,” said Werner Cautreels, PhD, CEO of Traws Pharma.